Not surprisingly, the potential of covalent inhibitors as successful drug candidates has attracted many organizations to perform research in this field. Our analysis of the literature since 2000 has shown thousands of organizations have published at least one journal article discussing covalent inhibitors, leading to over 10,000 articles total as of the date this publication. The greatest number of these articles were published by academic institutions with the University of California, Berkeley, the Chinese Academy of Sciences, Scripps Institute and Harvard Medical School all publishing more than 80 articles. The commercial sector has also shown considerable interest with Pfizer, AstraZeneca and Novartis being the most prolific in terms of publications. Of note, Pfizer stood out with more than 80 publications related to covalent inhibitors, more than twice as many as any other company (Figure ). The commercial potential of covalent inhibitor therapeutics has led to a correspondingly large number of patents being filed and issued with hundreds of institutions filing at least one patent, leading to over 1,000 patents in total. Predictably, commercial organizations have the most patents with Merck, Janssen, AbbVie and Celgene leading the way. The number of patents published by academic institutions has increased steadily on an annual basis since 2000, with Fudan University in China publishing the most (Figure ).